0 5 10 15 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg APEX KSI-101 in MESI – Meaningful visual acuity gains of more than two lines of vision have been achieved with the top two dose levels tested 75 ETDRS Letters ETDRS Letters 60 65 70 75 80 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg Mean Change in BCVA in patients completing Week 12 Observed BCVA over time in patients completing Week 12 Preliminary results. As the APEX study is ongoing, final results may be different due to additional data collection or data cleaning. Includes only patients in the per protocol set that completed the Week 12 visit by the cutoff date of 14-Jul-25 and meet all the eligibility criteria. Excludes one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion) 2.5 mg 9 9 9 9 9 5 mg 8 8 8 8 8 10 mg 10 10 10 10 10 N values N values Weeks Weeks 2.5 mg 9 9 9 9 9 5 mg 8 8 8 8 8 10 mg 10 10 10 10 10